VACC

Vaccitech plc is a clinical-stage biopharmaceutical company focused on developing cutting-edge T-cell immunotherapeutics and vaccines. Their mission is to treat and prevent a variety of infectious diseases and cancers. The company's therapeutic pipeline includes several programs undergoing clinical evaluation: VTP-300 is in Phase 1/2a clinical trials for chronic hepatitis B. VTP-200 is also in Phase 1/2a development, targeting human papillomavirus (HPV) infection. VTP-850 is progressing through Phase 1/2 clinical studies for prostate cancer. VTP-600 is engaged in Phase 1/2a trials for non-small cell lung cancer. In terms of prevention, their prophylactic initiatives feature: VTP-400, which is in a preclinical stage, designed to combat herpes zoster (shingles). VTP-500, which has concluded Phase 1 clinical trials for Middle East respiratory syndrome (MERS). Notably, Vaxzevria, a preventive vaccine against COVID-19 infection, is also part of their offerings. Established in 2016, the company was originally named Vaccitech Rx Limited before adopting its current name, Vaccitech plc, in March 2021. Vaccitech plc is headquartered in Oxford, United Kingdom.